



DO NOT enter
5/12/05
12/12/05

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No.05-860-US)
(Formerly Case. No. 13761-7065)

In re Application of:)
Laurie DeLeve)
Serial No.: 10/086,072) Group Art Unit: 1617
International Filing Date: February 27, 2002) Examiner: Sharareh
For: Compositions and methods for preventing) Confirmation No.: 1401
and treating sinusoidal obstruction syndrome)
and radiation-induced liver disease)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO THE OFFICE ACTION MAILED AUGUST 26, 2005

Sir:

Responsive to the Office Action mailed August 26, 2005, Applicants respectfully request reconsideration of the pending claims in view of the following amendments and remarks.

DO NOT
enter
SJA

In the claims

1. (Previously presented) A method for prophylaxis or treating Sinusoidal Obstruction Syndrome in a human patient in need thereof, comprising administering an effective amount of a matrix metalloprotease inhibitor that inhibits up-regulation of MMP-9 and/or MMP-2 isoenzymes, wherein the matrix metalloprotease inhibitor is selected from the group consisting of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid, Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[[4-methoxysulfonyl]3-picolyl)amino]-3-methylbutamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, and Periostat.

2. (Previously presented) A method for prophylaxis or treating chemotherapy- or radiation-induced liver disease in a human patient in need thereof, comprising administering an effective amount of a matrix metalloprotease inhibitor that inhibits up-regulation of MMP-9 and/or MMP-2 isoenzymes, wherein the matrix metalloprotease inhibitor is selected from the group consisting of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid, Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[[4-methoxysulfonyl]3-picolyl)amino]-3-methylbutamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, and Periostat.

3. (Previously presented) The method of claim 2, wherein said chemotherapy-induced liver disease includes Sinusoidal Obstruction Syndrome, nodular regenerative hyperplasia peliosis hepatic, immunosuppression-induced hepatic venoocclusive disease, and sinusoidal dilatation.

4-20. (Canceled)